Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

EVAS2 IDE Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study (EVAS2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03298477
Recruitment Status : Recruiting
First Posted : October 2, 2017
Last Update Posted : August 29, 2019
Sponsor:
Information provided by (Responsible Party):
Endologix

Brief Summary:
Prospective, multicenter, single arm study with consecutive, eligible subject enrollment at each site. All subjects will undergo the Endovascular Aneurysm repair procedure with the Nellix System.

Condition or disease Intervention/treatment Phase
Abdominal Aortic Aneurysm Without Rupture Device: Nellix® System Not Applicable

Detailed Description:
This study will evaluate the safety and effectiveness of the Nellix System among a wide range of physicians and in consecutively enrolled subjects to assess safety and effectiveness outcomes. Following appropriate government and ethics committee/IRB approval the Nellix® EndoVascular Sealing System will be implanted into eligible patients who are adequately informed and have consented to join the study. Enrolled patients will undergo a high resolution, contrast-enhanced computed tomography angiography (CT) scan of the relevant aortic and aortoiliac vasculature within three months of the scheduled procedure and at specified follow-up intervals post-implantation. Follow-up visits will occur at 30 days, 6 months, and annually to 5 years to assess aneurysm morphology, the status of the implanted devices, and relevant laboratory test results.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Prospective, multicenter, single arm study with consecutive, eligible subject enrollment at each site. All subjects will undergo the Endovascular Aneurysm repair procedure with the Nellix System. Sites have been chosen with a suitable research infrastructure and physician experience in endovascular aneurysm repair to ensure adequate enrollment. Subjects will be followed procedurally to discharge, at 30 days (primary safety endpoint), six months, one year (primary effectiveness endpoint) and annually thereafter to five years (total follow-up commitment).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix System IDE Study (EVAS 2 Confirmatory IDE Study)
Actual Study Start Date : December 1, 2017
Estimated Primary Completion Date : May 2020
Estimated Study Completion Date : May 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Single Arm
Single Arm Safety and Effectiveness Confirmatory Study of EVAS using the Nellix® System
Device: Nellix® System
Endovascular Abdominal Aortic Aneurysm Repair using the Nellix® System




Primary Outcome Measures :
  1. Incidence of Major Adverse Events (MAE) [ Time Frame: 30 days ]
    All cause mortality, bowel ischemia, myocardial infarction, paraplegia, renal failure, respiratory failure, stroke, procedural blood loss >1,000cc

  2. Rate of Treatment Success [ Time Frame: 1 year ]
    Procedural technical success and the absence of aneurysm rupture, conversion to open surgical repair, Type I endoleak at 12 months, Type III endoleak at 12 months, aneurysm enlargement, secondary procedure for resolution of endoleak (Type I or III), limb occlusion, migration, aneurysm sac expansion and/or a device defect



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA

A patient who meets all of the following criteria potentially may be included in the study:

  1. Male or female at least 18 years old;
  2. Informed consent form understood and signed
  3. Patient agrees to all follow-up visits;
  4. Abdominal aortic aneurysm with sac diameter ≥5.0cm, or ≥4.5cm which has increased by ≥0.5cm within the last 6 months, or or which exceeds 1.5 times the transverse dimension of an adjacent non-aneurysmal aortic segment. No AAA <4 cm will be included.
  5. Anatomically eligible for the Nellix System (per Instructions For Use):

    1. Adequate iliac/femoral access compatible with the required delivery systems (diameter ≥6 mm);
    2. Aneurysm blood lumen diameter ≤60mm;
    3. Proximal non-aneurysmal aortic neck: length ≥10mm; diameter 18 to 28mm; angle ≤60° to the aneurysm sac;
    4. Most caudal renal artery to each hypogastric artery length ≥100mm;
    5. Common iliac artery lumen diameter between 9 and 35mm;
    6. Distal iliac artery seal zone with length of ≥10mm and diameter range of 9 to 25mm;
    7. Ability to preserve at least one hypogastric artery.
    8. Ratio of maximum aortic aneurysm diameter to maximum aortic blood lumen diameter <1.40

EXCLUSION CRITERIA

A patient who meets none of the following criteria potentially may be included in the study:

  1. Life expectancy <2 years as judged by the Investigator;
  2. Psychiatric or other condition that may interfere with the study;
  3. Participating in another clinical study;
  4. Known allergy or contraindication to any device material;
  5. Coagulopathy or uncontrolled bleeding disorder;
  6. Ruptured, leaking or mycotic aneurysm;
  7. Serum creatinine (S-Cr) level >2.0 mg/dL;
  8. CVA or MI within three months of enrollment/treatment;
  9. Aneurysmal disease of the descending thoracic aorta;
  10. Clinically significant mural thrombus within the proximal landing zone (minimum 10mm) of the infrarenal non-aneurysmal neck (>5mm thickness over >50% circumference);
  11. Connective tissue diseases (e.g., Marfan Syndrome);
  12. Unsuitable vascular anatomy that may interfere with device introduction or deployment;
  13. Pregnant (female of childbearing potential only).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03298477


Contacts
Layout table for location contacts
Contact: Helen Van 949-452-2532 hvan@endologix.com

  Show 33 Study Locations
Sponsors and Collaborators
Endologix
Investigators
Layout table for investigator information
Principal Investigator: Jeffrey Carpenter, MD Cooper Hospital

Layout table for additonal information
Responsible Party: Endologix
ClinicalTrials.gov Identifier: NCT03298477     History of Changes
Other Study ID Numbers: CP-0008 EVAS2 IDE
First Posted: October 2, 2017    Key Record Dates
Last Update Posted: August 29, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Aneurysm
Aortic Aneurysm
Aortic Aneurysm, Abdominal
Rupture
Vascular Diseases
Cardiovascular Diseases
Aortic Diseases
Wounds and Injuries